The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
“We are advancing our SERENITY At-Home trial to pursue the near-term growth opportunity for treating acute agitation associated with bipolar disorders or schizophrenia in the outpatient setting. At ...
Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.
Chronic inflammation has been shown to negatively affect the whole body, from cognition to joint health. Despite these ...
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...
In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...
Schizophrenic drug user, Gregor Bauld, who stabbed his mother to death outside their £1m home after becoming convinced she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback